1Farmer RG, Michener WM, Mortimer EA. Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterol, 1980, 9(2) : 271 - 277.
2Stokkers PCF, Reitsma PH, Tytgat GNJ, et al. HLA-DR and-DQ phenotypes in inflammatory bowel disease: A meta-analysis. Gut, 1999, 45(3) : 395- 401.
3Hugot JP, Laurent-Puig P, Gower-Rousseau C, et al. Mapping of susceptibility locus for Crohn's disease on chromosome 16. Nature, 1996, 379(29) : 821- 823.
4Rioux JD, Silverberg MS, Dely MJ, et al. Genome-wide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet, 2000, 66(6): 1863- 1870.
5Gasche C, Bakos S, Dejaco C, et al. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J Clin Immunol, 2000, 20 (5) : 362 - 370.
6Hyams JS. Use of infliximab in the treatment of Crohn' s disease in children and adolescents.J Pediatr Gastroenterol Nurt, 2001, 33(suppl 1) : 36- 39.
7Gitnick G. Current views of the etiology of inflammatory bowel disease. Semin Pediatr Surg, 1994,3(1) : 2- 7.
8Coulson WF. Pathological features of inflammatory bowel disease in childhood. Semin Pediatr Surg, 1994, 3(1) : 8- 14.
9Barden L, Lipson A, Pert P, et al. Mesalazine in childhood inflammatory bowel disease.Aliment Pharmacol Ther, 1989, 3(6) : 597- 603.
10Kundhal P, Zachos M, Holmes JL, et al. Controlled ileal release budesonide in pediatric Crohn disease: Efficacy and effect on growth.J Pediatr Gastroenterol Nutr, 2001,33(1) : 75-80.
